Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Glucocorticoid steroids such as prednisone are prescribed for chronic muscle conditions such as Duchenne muscular dystrophy, where their use is associated with prolonged ambulation. The positive effects of chronic steroid treatment in muscular dystrophy are paradoxical because these steroids are also known to trigger muscle atrophy. Chronic steroid use usually involves once-daily dosing, although weekly dosing in children has been suggested for its reduced side effects on behavior. In this work, we tested steroid dosing in mice and found that a single pulse of glucocorticoid steroids improved sarcolemmal repair through increased expression of annexins A1 and A6, which mediate myofiber repair. This increased expression was dependent on glucocorticoid response elements upstream of annexins and was reinforced by the expression of forkhead box O1 (FOXO1). We compared weekly versus daily steroid treatment in mouse models of acute muscle injury and in muscular dystrophy and determined that both regimens provided comparable benefits in terms of annexin gene expression and muscle repair. However, daily dosing activated atrophic pathways, including F-box protein 32 (Fbxo32), which encodes atrogin-1. Conversely, weekly steroid treatment in mdx mice improved muscle function and histopathology and concomitantly induced the ergogenic transcription factor Krüppel-like factor 15 (Klf15) while decreasing Fbxo32. These findings suggest that intermittent, rather than daily, glucocorticoid steroid regimen promotes sarcolemmal repair and muscle recovery from injury while limiting atrophic remodeling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288 · cited 1×
“All original microarray data were deposited in the NCBI’s Gene Expression Omni-bus (65) (GEO GSE95682).”
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 1×
“We analyzed Fbxo32 , which encodes atrogin-1 (also known as MAFbx), an important mediator of muscle atrophy (30, 31).”
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012 · cited 1×
“We analyzed Fbxo32, which encodes atrogin-1 (also known as MAFbx), an important mediator of muscle atrophy (30, 31).”
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Annexin A1 and glucocorticoids as effectors of the resolution of inflammation
Perretti, M., & D'Acquisto, F. (2009) · Nature Reviews Immunology · doi:10.1038/nri2470 · Cited by 915
Milan, G., Romanello, V., Pescatore, F., Armani, A., Paik, J.-H., Frasson, L., Seydel, A., Zhao, J., Abraham, R., Goldberg, A. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7670 · Cited by 709
Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions
Zentner, G. E., Tesar, P. J., & Scacheri, P. C. (2011) · Genome Research · doi:10.1101/gr.122382.111 · Cited by 564
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Gong, S., Miao, Y.-L., Jiao, G.-Z., Sun, M.-J., Li, H., Lin, J., Luo, M.-J., & Tan, J.-H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117503 · Cited by 460
Cited by
Kraemer, W. J., Ratamess, N. A., Hymer, W. C., Nindl, B. C., & Fragala, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00033 · Cited by 300
Geisler, J. G. (2019) · Cells · doi:10.3390/cells8030280 · Cited by 104
“In young boys, it dampens inflammation, but in later years accelerates muscle atrophy, suggested that intermediate dosing may provide a better balance [148].”
BackgroundDemonbreun, A. R., Fallon, K. S., Oosterbaan, C. C., Vaught, L. A., Reiser, N. L., Bogdanovic, E., Velez, M. P., Salamone, I. M., Page, P. G. T., Hadhazy, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf0376 · Cited by 32
Self-citationBencze, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010362 · Cited by 20
Metadata
- Authors
- Quattrocelli, M., Barefield, D. Y., Warner, J. L., Vo, A. H., Hadhazy, M., Earley, J. U., Demonbreun, A. R., & McNally, E. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-05-08
- Volume
- 127
- Issue
- 6
- Pages
- 2418-2432
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2611567550
- Cited by
- 139
- References
- 11
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. https://app.cochat.ai/papers/10.1172/jci91445
- The paper
- Quattrocelli, M., Barefield, D. Y., Warner, J. L., Vo, A. H., Hadhazy, M., Earley, J. U., Demonbreun, A. R., & McNally, E. M. (2017). Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. Journal of Clinical Investigation. https://doi.org/10.1172/jci91445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.